Collaboration integrates MERCURIUS DRUG-seq technologies with Revvity’s screening portfolio, enabling scalable transcriptomic profiling for next-generation drug discovery and AI-driven research
From a $10 billion bioeconomy to over $190 billion, indigenous CAR-T therapy, and a booming startup ecosystem highlight 12 years of transformation in India’s science and technology landscape
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Veteran quality professional with over 20 years of industry experience to lead quality operations at Unit-4 API manufacturing facility
Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
New hit discovery service combines integrated DNA-Encoded Library screening, structural biology, biophysics, and X-ray crystallography
New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies
Samelisant will be the centerpiece of Suven’s scientific presence
The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream
Partnership will provide funding, incubation, mentorship, and industry exposure for ventures in healthcare, pharmaceuticals, biotechnology, medical technology, and agriculture
Subscribe To Our Newsletter & Stay Updated
